What is Healthlynked's earnings per share (EPS)?

Healthlynked (HLYK) reported diluted earnings per share of $-1.16 for fiscal year 2025. This represents a -5700.0% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Healthlynked Financials

HLYK

Source SEC Filings (10-K/10-Q) Updated Mar 31, 2026 Currency USD FYE March

This page shows Healthlynked (HLYK) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Earnings Quality Low Quality

0.52x

For every $1 of reported earnings, Healthlynked generates $0.52 in operating cash flow (-$1.7M OCF vs -$3.3M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-0.4x

Healthlynked earns $-0.4 in operating income for every $1 of interest expense (-$84K vs $204K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$2.0M

YoY-33.4%

5Y CAGR-20.1%

Healthlynked generated $2.0M in revenue in fiscal year 2025. This represents a decrease of 33.4% from the prior year.

EBITDA

$18K

YoY+100.4%

Healthlynked's EBITDA was $18K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 100.4% from the prior year.

Net Income

-$3.3M

YoY+46.5%

Healthlynked reported -$3.3M in net income in fiscal year 2025. This represents an increase of 46.5% from the prior year.

EPS (Diluted)

$-1.16

YoY-5700.0%

Healthlynked earned $-1.16 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 5700.0% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$1.7M

YoY+50.9%

Healthlynked generated -$1.7M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 50.9% from the prior year.

Cash & Debt

N/A

Dividends Per Share

N/A

Shares Outstanding

YoY+4.2%

Healthlynked had 3M shares outstanding in fiscal year 2025. This represents an increase of 4.2% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

-4.2%

YoY+151.3pp

5Y CAGR+45.9pp

Healthlynked's operating margin was -4.2% in fiscal year 2025, reflecting core business profitability. This is up 151.3 percentage points from the prior year.

Net Margin

-163.8%

YoY+40.0pp

5Y CAGR-70.0pp

Healthlynked's net profit margin was -163.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 40.0 percentage points from the prior year.

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

$3K

YoY+0.0%

5Y CAGR-36.4%

Healthlynked invested $3K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 0.0% from the prior year.

HLYK Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$2.0M-33.4%	$3.0M-47.4%	$5.7M-2.3%	$5.9M-9.8%	$6.5M+5.9%	$6.1M
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$2.0M-33.0%	$3.0M-16.1%	$3.6M-20.8%	$4.6M-7.1%	$4.9M+60.9%	$3.1M
Operating Income	-$84K+98.2%	-$4.7M-12.7%	-$4.2M+52.1%	-$8.7M-62.4%	-$5.3M-73.5%	-$3.1M
Interest Expense	$204K	N/A	$21K	$0	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$3.3M+46.5%	-$6.1M-505.8%	-$1.0M+88.5%	-$8.8M+15.3%	-$10.4M-80.9%	-$5.8M
EPS (Diluted)	$-1.16-5700.0%	$-0.02	$0.00+100.0%	$-0.04+20.0%	$-0.05-25.0%	$-0.04

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$389K-34.4%	$592K-23.5%	$774K+25.1%	$619K+4.9%	$590K-25.8%	$795K-20.8%	$1.0M+7.8%	$931K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	$501K+10.8%	$452K-28.2%	$629K+15.2%	$546K-13.6%	$632K-26.7%	$861K-13.8%	$999K+8.8%	$918K
Operating Income	-$530K-21.6%	-$435K+29.5%	-$617K+17.5%	-$749K+55.2%	-$1.7M-54.8%	-$1.1M+8.4%	-$1.2M-5.9%	-$1.1M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	$6K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$852K-21.5%	-$701K+33.3%	-$1.1M+14.6%	-$1.2M+37.7%	-$2.0M-28.1%	-$1.5M-11.0%	-$1.4M-7.9%	-$1.3M
EPS (Diluted)	$-0.30	$0.00	$0.00	N/A	$-0.70-6900.0%	$-0.01	$0.00	N/A

HLYK Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	N/A	$2.2M-48.1%	$4.3M-6.6%	$4.6M-57.2%	$10.7M+33.2%	$8.0M
Current Assets	N/A	$1.6M+150.1%	$656K-69.4%	$2.1M-41.3%	$3.7M+804.6%	$404K
Cash & Equivalents	N/A	$76K-69.2%	$247K+299.4%	$62K-98.1%	$3.3M+1929.6%	$162K
Inventory	N/A	$45K-66.5%	$133K-30.9%	$193K+42.9%	$135K+41.7%	$95K
Accounts Receivable	N/A	N/A	$21K-71.1%	$72K-16.2%	$86K-1.0%	$87K
Goodwill	N/A	N/A	N/A	$320K-58.2%	$766K-33.3%	$1.1M
Total Liabilities	N/A	$5.4M+54.0%	$3.5M-18.5%	$4.3M+22.2%	$3.5M-47.7%	$6.7M
Current Liabilities	N/A	$4.7M+94.4%	$2.4M-30.6%	$3.5M+81.2%	$1.9M-60.7%	$4.9M
Long-Term Debt	N/A	N/A	N/A	$45K-55.6%	$101K+464.3%	$18K
Total Equity	N/A	-$3.1M-488.9%	$805K+155.9%	$314K-95.6%	$7.2M+433.6%	$1.4M
Retained Earnings	N/A	-$48.2M-14.6%	-$42.0M-2.5%	-$41.0M-27.4%	-$32.2M-47.8%	-$21.8M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$1.8M-4.5%	$1.8M-10.2%	$2.1M-7.5%	$2.2M-19.4%	$2.8M-28.5%	$3.9M-0.8%	$3.9M-9.1%	$4.3M
Current Assets	$1.5M-1.0%	$1.6M-0.5%	$1.6M-4.5%	$1.6M-10.0%	$1.8M-9.0%	$2.0M+5.8%	$1.9M+189.0%	$656K
Cash & Equivalents	$11K-46.0%	$20K-9.3%	$22K-70.8%	$76K+409.7%	$15K-91.3%	$173K+635.2%	$23K-90.5%	$247K
Inventory	$32K+15.9%	$28K-14.5%	$32K-27.8%	$45K-43.3%	$79K-18.3%	$96K-29.2%	$136K+2.2%	$133K
Accounts Receivable	N/A	N/A	N/A	N/A	$26K-33.7%	$39K+14.7%	$34K+61.2%	$21K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$7.2M+9.0%	$6.6M+6.6%	$6.2M+15.7%	$5.4M+14.1%	$4.7M+9.5%	$4.3M+16.8%	$3.7M+5.6%	$3.5M
Current Liabilities	$6.7M+10.1%	$6.1M+9.4%	$5.6M+19.4%	$4.7M+23.2%	$3.8M+12.1%	$3.4M+26.0%	$2.7M+11.7%	$2.4M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	-$5.4M-14.3%	-$4.8M-14.9%	-$4.1M-32.2%	-$3.1M-61.9%	-$1.9M-355.3%	-$425K-291.7%	$221K-72.5%	$805K
Retained Earnings	-$50.8M-1.7%	-$49.9M-1.4%	-$49.2M-2.2%	-$48.2M-2.6%	-$46.9M-4.4%	-$45.0M-3.5%	-$43.4M-3.3%	-$42.0M

HLYK Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$1.7M+51.0%	-$3.5M+15.7%	-$4.1M+5.0%	-$4.4M-15.7%	-$3.8M-78.1%	-$2.1M
Capital Expenditures	$3K0.0%	$3K+73.2%	$2K-93.6%	$24K+22.4%	$19K-23.0%	$25K
Free Cash Flow	-$1.7M+50.9%	-$3.5M+15.7%	-$4.1M+5.5%	-$4.4M-15.8%	-$3.8M-76.9%	-$2.1M
Investing Cash Flow	$125K-70.4%	$422K-88.0%	$3.5M+743.6%	-$545K-59.6%	-$341K-118.8%	$1.8M
Financing Cash Flow	$1.5M-46.6%	$2.9M+252.0%	$824K-50.9%	$1.7M-76.8%	$7.2M+1929.3%	$357K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	$8K	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$444K-6.4%	-$418K+3.5%	-$433K+41.8%	-$744K+28.3%	-$1.0M-20.8%	-$859K-0.4%	-$855K+28.3%	-$1.2M
Capital Expenditures	N/A	N/A	N/A	$0	$0	$0-100.0%	$3K	$0
Free Cash Flow	N/A	N/A	N/A	-$744K+28.3%	-$1.0M-20.8%	-$859K-0.1%	-$857K+28.1%	-$1.2M
Investing Cash Flow	N/A	N/A	N/A	$425K	$0	$0+100.0%	-$3K-100.2%	$1.2M
Financing Cash Flow	$435K+4.7%	$415K+9.7%	$379K-0.3%	$380K-56.8%	$879K-12.8%	$1.0M+59.0%	$634K+213.8%	$202K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

HLYK Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-4.2%+151.3pp	-155.5%-82.9pp	-72.5%+75.3pp	-147.8%-65.8pp	-82.0%-32.0pp	-50.1%
Net Margin	-163.8%+40.0pp	-203.8%-186.1pp	-17.7%+132.8pp	-150.5%+9.8pp	-160.3%-66.4pp	-93.8%
Return on Equity	N/A	N/A	-125.8%+2677.8pp	-2803.5%-2659.0pp	-144.5%+281.8pp	-426.3%
Return on Assets	N/A	-275.8%-252.2pp	-23.6%+168.8pp	-192.5%-95.1pp	-97.4%-25.7pp	-71.7%
Current Ratio	N/A	0.35+0.1	0.27-0.3	0.62-1.3	1.90+1.8	0.08
Debt-to-Equity	N/A	-1.71-6.0	4.32+4.2	0.14+0.1	0.010.0	0.01
FCF Margin	-85.7%+30.5pp	-116.2%-43.8pp	-72.5%+2.4pp	-74.9%-16.6pp	-58.3%-23.4pp	-34.9%

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-136.3%-62.8pp	-73.5%+6.2pp	-79.7%+41.2pp	-121.0%+162.2pp	-283.2%-147.4pp	-135.8%-18.5pp	-117.3%+2.1pp	-119.4%
Net Margin	-219.2%-100.9pp	-118.3%+17.4pp	-135.7%+63.0pp	-198.8%+135.6pp	-334.4%-140.6pp	-193.8%-55.6pp	-138.2%-0.1pp	-138.1%
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	-626.5%-466.7pp	-159.8%
Return on Assets	-48.3%-10.3pp	-37.9%+13.2pp	-51.1%+4.3pp	-55.3%+16.2pp	-71.5%-31.6pp	-39.9%-4.2pp	-35.7%-5.6pp	-30.0%
Current Ratio	0.23-0.0	0.25-0.0	0.28-0.1	0.35-0.1	0.48-0.1	0.59-0.1	0.70+0.4	0.27
Debt-to-Equity	-1.32+0.1	-1.39+0.1	-1.50+0.2	-1.71+0.7	-2.43+7.7	-10.09-26.7	16.57+12.2	4.32
FCF Margin	N/A	N/A	N/A	-120.1%+55.6pp	-175.7%-67.7pp	-108.0%-22.6pp	-85.4%+42.7pp	-128.0%

Similar Companies

Revitalist Lifes RVLWF

$5.4M

Selectis Health Inc GBCS

$12.9M

Xcelerate Inc XCRT

$4.3M

Veltex VLXC

$3.9M

Biocorrx Inc BICX

$9.5M

Frequently Asked Questions

What is Healthlynked's annual revenue?

Healthlynked (HLYK) reported $2.0M in total revenue for fiscal year 2025. This represents a -33.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Healthlynked's revenue growing?

Healthlynked (HLYK) revenue declined by 33.4% year-over-year, from $3.0M to $2.0M in fiscal year 2025.

Is Healthlynked profitable?

No, Healthlynked (HLYK) reported a net income of -$3.3M in fiscal year 2025, with a net profit margin of -163.8%.

What is Healthlynked's EBITDA?

Healthlynked (HLYK) had EBITDA of $18K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Healthlynked's operating margin?

Healthlynked (HLYK) had an operating margin of -4.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Healthlynked's net profit margin?

Healthlynked (HLYK) had a net profit margin of -163.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Healthlynked's free cash flow?

Healthlynked (HLYK) generated -$1.7M in free cash flow during fiscal year 2025. This represents a 50.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Healthlynked's operating cash flow?

Healthlynked (HLYK) generated -$1.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Healthlynked's capital expenditures?

Healthlynked (HLYK) invested $3K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does Healthlynked have outstanding?

Healthlynked (HLYK) had 3M shares outstanding as of fiscal year 2025.

Are Healthlynked's earnings high quality?

Healthlynked (HLYK) has an earnings quality ratio of 0.52x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Healthlynked cover its interest payments?

Healthlynked (HLYK) has an interest coverage ratio of -0.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.